$2.5 Million Revenue Medical Device Manufacturing in Midwest Seeking Equity Partner to Scale

American Healthcare Capital is proud to be the exclusive representative of a Medical Device Manufacturer and Distributor for sale. This opportunity involves the sale of a well-established therapeutic technology company specializing in FDA-cleared Class IV laser and shockwave therapy equipment. Headquartered in the Midwest, the company provides advanced, non-invasive medical devices to a broad customer base of healthcare professionals across North America.

Founded by a seasoned healthcare professional with decades of clinical experience, the company has rapidly evolved into a recognized innovator in the field of therapeutic technology. Under new ownership since 2023, the business is focused on expanding its direct sales infrastructure, optimizing distributor partnerships, and growing market share through both domestic and international channels.

With high product margins, a scalable team structure, and over 500 active customers, this business is well-positioned for accelerated growth under new leadership. The current owners are open to remaining involved post-transaction, making this an ideal opportunity for strategic or financial buyers seeking expansion in the medical device or healthcare technology sectors.

Key Highlights:

Established brand with clinical credibility and FDA-cleared products

Over 500 active customers, with repeat purchase behavior

Lean operating structure with 4 employees and 2 independent contractors

High-margin, cash-based revenue model supported by external financing partners

Ongoing buildout of a direct sales channel to increase profitability and control

Renewed regional distributor network targeting higher-quality partners

Significant growth potential via product expansion, geographic diversification, and potential entry into recurring revenue models

Financial Highlights

The company generated nearly $1.9 million in revenue in 2024, with a net adjusted EBITDA of $504,000 since the new owners took over the company in the last quarter of 2023. In 2025, the company generated ~$2.1 million in revenue with a net adjusted EBIDTA of ~$695,000 and track to grow to $2,500,000 Revenue and $750,000 in EBITDA in 2026. There was additional principal paydown of SBA loan in amount of $197,035 in 2024 that is not included in the EBITDA.

The business is currently on a modest upward growth trajectory as new sales strategies and infrastructure investments take hold. The company carries no outstanding liabilities, lawsuits, or tax issues.

Reason for Partial Exit

The owners are seeking a strategic/capital partner to assist them in scaling company to the next level. To accelerate growth, the owners are open to selling majority stake plus an earn out in their company while retaining significant equity to continue growing the company.

Asking Price

The valuation and asking price shall be determined through discussions and negotiations. The asking price excludes cash, inventory, accounts receivables, working capital and any real estate properties.

The asking price excludes cash, inventory, accounts receivables, working capital and any real estate properties

$2.8 Million Revenue Locums Tenens Staffing Agency in Florida

American HealthCare Capital is pleased to exclusively introduce a exclusive nationwide locum tenens staffing company specializing in Physicians (MD/DO), Nurse Practitioners, Physicians Assistants, Dentists, and CRNAs. The business was founded in 2018 and is located in South Florida.

This full-service healthcare staffing agency simplifies the hiring process for its clients and providers. The company manages key operational aspects such as malpractice insurance, travel arrangements, credentialing, payroll, and billing to ensure a smooth and efficient experience. They focus on building long-term relationships and have partnered with over 680 clients nationwide, maintaining a high client retention rate. The company’s business model uses dedicated Account Managers and Recruiters to provide personalized service.

Operations are further strengthened by a fully customized CRM platform that enables robust reporting, streamlined record-keeping, and access to an expansive database covering nearly every specialty in medicine and dentistry. This infrastructure positions the company to quickly adapt and respond to evolving client needs.

Financial Overview

The company achieved its strongest financial performance in revenue following the pandemic, closing 2023 with $2.5 million in total revenue. In 2024, revenue reached $2.25 million with an adjusted EBITDA of $240,000. Projections for 2025 indicate the best year to date, with revenue expected to exceed $2.7 million with an adjusted EBITDA of $643,000.

Exit Plan

The owners are seeking a sale or partnership for a 65% stake in the company. They are looking for a strategic partner to help accelerate nationwide growth in the healthcare staffing sector. The owners are committed to remain actively involved to support operations and drive expansion alongside the new ownership.

Asking Price

The asking price for this opportunity is $2,535,000 for 65% ownership of the company.

$3 Million Revenue Clinical Trial Company

American HealthCare Capital is pleased to introduce a clinical trial service business for sale that provides comprehensive healthcare, clinical research, and technology services to global pharmaceutical and biotech organizations. With a network of more than 1,600 registered clinical sites worldwide, including hospitals, private clinics, and research centers, the company has established strong partnerships with major sponsors such as Pfizer, GSK, and other industry leaders.

Clients benefit from a dedicated study manager who ensures each project is set up for success and managed with precision. Core services include:

• Network Sites – Business development, Protocol feasibility process, Study start-up and sponsor visits and communications for all network sites. The company also operates an offshore modern facility designed to support its overall operations.• Technology Access – A secure online portal offering an all-in-one platform for managing research activities and studies efficiently.• Patient Recruitment – Tailored recruitment strategies based on indication, demographics, and study timelines.• Budgeting Assistance – Expert support for study budgeting, with additional guidance for organizations new to clinical research.• Patient Management – Robust tracking and documentation tools to oversee enrollment, amendments, and progress across studies.• Learning Resources – Free access to professional courses, live instruction, and downloadable templates to support site success.

New Tech Platform

In addition to its established Clinical Research operations, the company is launching KerloSense, a next-generation technology platform that substantially enhances enterprise value. Designed to address inefficiencies in clinical research, KerloSense enables seamless global collaboration by connecting sponsors, clinical research facilities, and site management organizations (SMOs). With its scalable, all-in-one model, the platform introduces high-margin, recurring revenue opportunities while expanding market reach. Positioned as a disruptive force within the clinical research industry, KerloSense strengthens the company’s long-term growth trajectory and unlocks significant value creation for investors.

Key Features include:

• SITE SEARCH AND STUDY SEARCH- tailored search and filtering• BILLING & INVOICING-secure, seamless invoicing and payment management.• PATIENT MANAGEMENT-easy scheduling and invoicing for patient visits• LEARNIING MANAGEMENT SYSTEM-streamlined onboarding and training for research teams• SMO NETWORK MANAGEMENT- connect with SMO’s and recruitment companies to optimize success.

Financial Performance

The company has demonstrated consistent year-over-year growth and is positioned for its strongest performance yet. In 2023, revenue reached $2.8 million with an EBITDA of $614,500. In 2024, revenue grew to just over $3 million with EBITDA of $685,000. Projections for 2025 exceed $4 million in revenue and $875,000 in EBITDA, supported by multiple new studies and expanded revenue streams.

Exit Strategy

With a strong track record, proven service model, and scalable infrastructure, the company is strategically positioned to drive continued expansion and deliver sustained returns. The owner is pursuing an earn-out purchase structure, with mutually defined terms anchored by an initial valuation at closing and a follow-up valuation one-year post-acquisition. Supported by a healthy pipeline and significant market demand, the business offers compelling growth potential and value creation for investors. The founders remain flexible and are prepared to stay actively engaged for up to one year if desired, ensuring continuity, or to provide a structured transition with a defined exit strategy.

Asking Price

The sellers have allocated the asking price between the two components of the business: the established Clinical Research operations, valued at $7 million, and the newly developed Tech Platform, valued at $3 million, resulting in a total asking price of $10 million, plus an earnout component.

$3.1 Million Revenue Hormone Replacement Therapy (HRT), Medical Spa, and Aesthetics Practice, in South Florida

American HealthCare Capital is pleased to exclusively represent a full-spectrum med-spa offering primarily Hormone Replacement Therapy, plus a blend of anti-aging, aesthetic, wellness, and sexual health services in South Florida. This physician-led medical spa and wellness clinic was established in 2018 and has earned a strong reputation as a trusted destination for clients seeking both vitality and aesthetics, offering an uncommon combination of advanced medicine, sexual wellness, and non-invasive cosmetic treatments.

With a focus on HRT, which represents about 70% of total revenue, the practice employs cutting-edge technology and medically backed treatments, this medical spa offers its clients both cosmetic enhancement and wellness services to address their beauty and self-care needs. Each client receives a customized consultation to develop a treatment plan that aligns with their beauty goals, skin type, and body concerns.

In a competitive analysis, the Company stands out with its medically sophisticated, integrated approach across aesthetics, wellness, and longevity—an appealing model for higher-income or medically-minded clients in the market.

The company accepts private-pay clients only, does not bill insurance, and therefore collects all payments from the patient.

Facility

The company leases a beautiful 3,000 square foot space in a modern medical building on a main thoroughfare in an affluent market. It includes multiple private treatment rooms, a salt room, a relaxation room, and a lounge within the office. It is an inviting, comfortable space designed for new patients to learn about services and feel at ease while consulting with the staff.

The company has over $1 million of state-of-the-art equipment including:

Softwave, OxyGeneo, Try-lift, Piq04, XEO, and Stellar M22, and EBOO machine, an Emcyte centrifuge, and several shockwave devices.

Financial Overview

The company has experienced significant revenue and earnings growth over the past few years, reflecting its strong market position and loyal customer base. Gross Revenue has increased over the past few years, reaching $3,003,515 in 2024. Adjusted EBITDA has also been on an upward trajectory, surpassing $500,000 in 2024. In 2025, they grossed $1,825,380 through July, putting them on pace to reach $3,129,222 by the end of the year. Adjusted EBITDA through July 2025 was $293,518, and they expect to reach $503,174 by year end.

Industry Note

In 2025, there has been a nationwide MedSpa market slowdown, with major players like Allergan and Galderma reporting similar trends of up to 30%, driven by broader economic and geopolitical factors, not company-specific issues.

Despite the dip, the Company has continued to demonstrate resilience, maintaining revenue growth and profitability through its affluent market, high-value service mix, and integrated medical approach.

This makes it an ideal acquisition platform for investors or physician-operators seeking to expand in one of the country’s most attractive markets.

Staff Overview

The company employs a dedicated team of 8 professionals, including the 2 provider-partners, a Nurse Practitioner and a Physician, all of whom are expected to stay on under new ownership. Staff consists of a Laser Tech; A Receptionist and Organizer; a Medical Assistant; 2 Sales and Wellness Consultants; and a Purchasing Manager for Meds and Compounds. The provider partners will assist during a transitional period to ensure the continued success of the business and will be available to remain indefinitely as well as the balance of the staff.

Asking Price

The asking price for this opportunity is $2.9 million, which does not include cash, receivables, or working capital.

$3.25 Million Revenue, AI Tech-Enabled Home Health Care RCM Business

American HealthCare Capital is pleased to exclusively present a growing Revenue Cycle Management business specializing in the Home Health field. The company has recently developed and put into practice a propriety, first-of-its-kind, AI-enabled coding and QA offering.

Financial Overview

Revenues in 2023 and 2024 were just under $3.0 million each year, up from $2.4 million in 2022. For 2025, the company expects revenues to increase to approximately $3.25 million. Adjusted EBITDA for 2025 is expected to come in at over $662,000 and the company’s pipeline of new business is very strong. Additionally, operating margins should continue to widen once the AI offering is fully implemented during the second half of 2025 and beyond.

Staff Overview

The company has a very deep, talented workforce based both onshore and offshore, employing over 150 highly experienced, educated and certified healthcare professionals. The management team is very strong and fully capable of operating the business. They will stay on post-sale, including the owner if desired.

Asking Price

As both the business and the AI technology are for sale, the asking price for this opportunity is $5 million, which does not include cash, receivables, or working capital.

$3.6 Million Revenue Manufacturer and Global Distributor of Healthcare Architectural Products based in the Southeastern United States

American HealthCare Capital is pleased to exclusively present a Manufacturer and Distributor of Healthcare Architectural Products for sale in the Southeastern United States. The Company provides architectural solutions for clinical environments including hospitals, surgi-centers, skilled nursing facilities, medical practices, and more. 

Products available include items such as advanced equipment management rails to specialized medical accessories that “reside” on the rails to enhance the efficiency and safety of the clinical environments. Solutions include, but are not limited to, rails and accessories, headwalls, modular environments, mobile applications, and mass casualty situations. The Company is proud to have served hundreds of healthcare clients (including the U.S. Military and U.S. Veterans Administration) in the United States, Europe, and Middle East, 75% of whom have been repeat customers over the years.

Financial Overview

The Company’s payor mix and/or sources of revenue are approximately 80% healthcare facility end-users and approximately 20% third (3rd) party distribution partners. In 2023, the Company achieved $2,284,473 in gross revenue with a net operating income of approximately $400,000. In 2024, the Company is trending significantly upwards to approximately $3,635,099 (9/30/24 annualized) in gross revenue with a net operating income of approximately $988,528 (9/30/24 annualized). At the present time, the Company is positioned for significant additional growth with the high and growing demand for solutions and products to enhance the efficiency and safety of clinical environments, active recruitment of additional sales representatives, continuing to participate in industry groups and trade shows, and recognition within the healthcare community, which a new owner could build upon.

Staff Overview

The current owners are interested in remaining with the Company for sale in a similar capacity for up to 2 more years to provide assistance for the new owner. Furthermore, the 15 administrative and manufacturing staff, 5 independent commissioned sales representatives, and 3 paid sales representatives are all expected to remain with the Company following the transition to a new owner.

Asking Price

The asking price for this opportunity is $7 million plus inventory on hand.